Home Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA (pembrolizumab)
 

Keywords :   


Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA (pembrolizumab)

2017-01-09 14:00:47| Merck.com - Product News

Dateline City: WILMINGTON, D.E. & KENILWORTH, N.J. Additional pivotal studies evaluating Incytes IDO1 inhibitor in combination with Mercks anti-PD-1 therapy in patients with non-small cell lung, renal, bladder and head and neck cancers expected to start in 2017 WILMINGTON, D.E. & KENILWORTH, N.J. Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of epacadostat, Incytes investigational oral selective IDO1 inhibitor, with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy. Language: English read more

Tags: with development program combination

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.03Amorepacific Patents Hair Growth Compositions with Camellia Kaempferol Glycoside
28.03Dry Shampoo That Provides Color Patented by Church & Dwight
28.03FTX's Sam Bankman-Fried sentenced to 25 years
28.03Pork producers donate 35,000 pounds of Dailys bacon to Utah Food Bank
28.03Post-Brexit tax to hit UK car exports to Canada
28.03Webinar series to focus management of beef on dairy crossbreds
28.03Secret papers show Post Office knew case was false
28.03LOccitane Travel Retail Debuts New Bodycare Range From Sol de Janeiro With Paris Pop-Up
More »